Nurtec ODT vs Leqembi
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Nurtec ODT | US Leqembi | |
|---|---|---|
| Generic name | rimegepant | lecanemab |
| Drug class | CGRP Receptor Antagonist | Anti-Amyloid Monoclonal Antibody |
| Treats | Migraine (acute and preventive) | Early Alzheimer's disease |
| Category | Neurology | Neurology |
| Manufacturer | Pfizer | Eisai |
| Year approved | 2020 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $190M | — |
| Common side effects | Nausea, Stomach pain, Indigestion, Allergic reactions | Brain swelling (ARIA), Brain bleeding (ARIA), Infusion reactions, Headache |
Nurtec ODT
Frequently asked questions
Is Nurtec ODT or Leqembi better?
Neither is universally "better." Nurtec ODT (rimegepant) and Leqembi (lecanemab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nurtec ODT and Leqembi?
Nurtec ODT is a CGRP Receptor Antagonist made by Pfizer, while Leqembi is a Anti-Amyloid Monoclonal Antibody made by Eisai. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nurtec ODT has the larger estimated TV advertising budget of the two.